Adicet Bio, Inc. (ACET)

US — Healthcare Sector
Peers: DSGN  ALXO  ADCT  AAON  ABCB  ACTG  ACIW 

Automate Your Wheel Strategy on ACET

With Tiblio's Option Bot, you can configure your own wheel strategy including ACET - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ACET
  • Rev/Share 0.0714
  • Book/Share 1.4643
  • PB 0.4662
  • Debt/Equity 0.1152
  • CurrentRatio 7.4794
  • ROIC -0.8477

 

  • MktCap 56837369.0
  • FreeCF/Share -1.1006
  • PFCF -0.5669
  • PE -0.5242
  • Debt/Assets 0.0942
  • DivYield 0
  • ROE -0.6848

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed ACET Guggenheim -- Buy -- $7 Sept. 30, 2024
Downgrade ACET H.C. Wainwright Buy Neutral -- -- Sept. 11, 2024

News

Adicet Bio (ACET) Upgraded to Buy: Here's Why
ACET
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
ACET
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

About Adicet Bio, Inc. (ACET)

  • IPO Date 2018-01-26
  • Website https://www.adicetbio.com
  • Industry Biotechnology
  • CEO Chen Schor BA, CPA,
  • Employees 152
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.